| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e8a6ac71dcbaa4cf653000e244d6292f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D491-056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate |
2021-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b5fb8e3cb499a984558b0c5caab0416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ccac3c5ad1124f2ebbdfc5b1b4a8906c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b15c087de32d8fe437895ed5b3eb24fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17bb72573d14f1c2ee6fc560abbd2716
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44012d558c22da60913b95d5f2d9f1ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_981a469dd064d22397c39ac48d8a266b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3270f3e86ee9648edc4fac73fa26883 |
| publicationDate |
2022-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022061202-A1 |
| titleOfInvention |
Compositions and methods for treating cancer |
| abstract |
The present disclosure relates to compounds that are capable penetrating to the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022152029-A1 |
| priorityDate |
2020-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |